Two infants with leukemia that were treated with genetically engineered immune cells from a donor found cancer free after an 18-month follow-up.

The infants were also given the standard of care chemotherapy along with the engineered T-cells but they previously failed to respond to chemo before the experimental treatment. This experiment treatment using engineered T-cells is known as CAR-T and initial phase I clinical trials are now underway.